During the last session, CRISPR Therapeutics AG (NASDAQ:CRSP)’s traded shares were 4.58 million, with the beta value of the company hitting 1.79. At the end of the trading day, the stock’s price was $59.0, reflecting an intraday loss of -1.80% or -$1.08. The 52-week high for the CRSP share is $63.68, that puts it down -7.93 from that peak though still a striking 49.08% gain since the share price plummeted to a 52-week low of $30.04. The company’s market capitalization is $5.10B, and the average intraday trading volume over the past 10 days was 4.76 million shares, and the average trade volume was 2.62 million shares over the past three months.
CRISPR Therapeutics AG (CRSP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.93. CRSP has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it.
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
CRISPR Therapeutics AG (CRSP) registered a -1.80% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.80% in intraday trading to $59.0, hitting a weekly high. The stock’s 5-day price performance is 14.19%, and it has moved by 40.18% in 30 days. Based on these gigs, the overall price performance for the year is 49.90%. The short interest in CRISPR Therapeutics AG (NASDAQ:CRSP) is 21.41 million shares and it means that shorts have 9.74 day(s) to cover.
The consensus price target of analysts on Wall Street is $65, which implies an increase of 9.23% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $65 and $65 respectively. As a result, CRSP is trading at a discount of -10.17% off the target high and -10.17% off the low.
While earnings are projected to return -25.48% in 2025, the next five years will return 5.55% per annum.
CRSP Dividends
CRISPR Therapeutics AG is due to release its next quarterly earnings on 2025-May-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
CRISPR Therapeutics AG insiders own 1.69% of total outstanding shares while institutional holders control 76.46%, with the float percentage being 77.78%. CAPITAL INTERNATIONAL INVESTORS is the largest shareholder of the company, while 529.0 institutions own stock in it. As of 2024-06-30, the company held over 7.87 million shares (or 9.2619% of all shares), a total value of $424.8 million in shares.
The next largest institutional holding, with 7.78 million shares, is of ARK INVESTMENT MANAGEMENT LLC’s that is approximately 9.1597% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $420.12 million.
Also, the Mutual Funds coming in first place with the largest holdings of CRISPR Therapeutics AG (CRSP) shares are ARK ETF Trust-ARK Innovation ETF and NEW PERSPECTIVE FUND . Data provided on May 31, 2025 indicates that ARK ETF Trust-ARK Innovation ETF owns about 7.05 shares. This amounts to just over 8.16 percent of the company’s overall shares, with a $415.78 million market value. The same data shows that the other fund manager holds slightly less at 2.55, or about 2.96% of the stock, which is worth about $150.64 million.
